Reply
Tue 1 May, 2007 09:40 am
This Supreme Court action is of interest to me because I'm reading "Internal Combustion", the story of the deplorable history of how patent fraud and manipulation were used to squeeze alternative fuels and vehicles out of the marketplace throughout the twentieth century in favor of highly polluting petroleum-based products---all because of greed---and creating the crisis in public and planetary health. Had this reform been in place, we might have had different automobile choices.---BBB
May 1, 2007
High Court Puts Limits on Patents
By LINDA GREENHOUSE
New York Times
WASHINGTON, April 30 ?- The Supreme Court, in its most important patent ruling in years, on Monday raised the bar for obtaining patents on new products that combine elements of pre-existing inventions.
If the combination results from nothing more than "ordinary innovation" and "does no more than yield predictable results," the court said in a unanimous opinion, it is not entitled to the exclusive rights that patent protection conveys. "Were it otherwise," Justice Anthony M. Kennedy wrote in the opinion, "patents might stifle, rather than promote, the progress of useful arts."
Because most inventions combine previously known elements, the court's approach to deciding what sort of combination is so "obvious" as to be ineligible for patent protection will have widespread application. The result will be to make patents harder to obtain and defend.
"Granting patent protection to advances that would occur in the ordinary course without real innovation retards progress," Justice Kennedy said. He added that such patents were also undesirable because they might deprive earlier innovations of "their value or utility."
Patent law experts said the ruling created a common sense standard that could have a broad impact.
"Nearly every patent that contains a combination of prior ideas is at risk because the court has dramatically broadened the standard of obviousness," said Cynthia Kernick, an intellectual property lawyer at Reed Smith in Pittsburgh.
Judges will have more leeway to dismiss patent infringement lawsuits without requiring a jury trial, and patent examiners, who generally grant patent applications unless they find prior references to the same invention, will now feel freer to deny claims, said Matthew Kreeger, an intellectual property lawyer at Morrison and Foerster in San Francisco.
"And we could see thousands of cases asking the Patent Office to re-examine patents it has already granted," said Mr. Kreeger, who was one of the lawyers who had prepared a brief filed by the Biotechnology Industry Organization in support of the patent. "It doesn't take a lot of resources to ask for a re-examination." To be eligible for a patent, an invention must be novel, useful and not "obvious" to a person of "ordinary skill" in the field. The Supreme Court case concerned a fairly typical dispute over whether a combination of old elements in a new way was new or simply "obvious" to any expert.
At issue was an adjustable gas pedal for use on cars and trucks equipped with electronic engine controls. How could the vehicle's computer tell the pedal's position? A Canadian company, KSR International, under contract to General Motors, solved the problem by mounting an electronic sensor at the pedal's fixed pivot point in order to communicate the necessary information.
A rival, Teleflex Inc., demanded royalties, claiming the device infringed its patent on an adjustable gas pedal equipped with an electronic sensor. KSR refused to pay on the ground that Teleflex had combined existing elements in an obvious manner and that its patent was therefore invalid. KSR won in Federal District Court in Detroit, but that decision was overturned in 2005 by the United States Court of Appeals for the Federal Circuit.
That court, in Washington, has exclusive jurisdiction over patent appeals. After years of permitting its judgments to stand unreviewed, the Supreme Court has begun to take an active interest in the Federal Circuit's cases and has overturned several, including a second case the justices decided on Monday in favor of Microsoft in a dispute with AT&T.
In granting judgment for KSR on Monday, in KSR International Co. v. Teleflex Inc., No. 04-1350, the Supreme Court listed several specific errors and "fundamental misunderstandings" in how the Federal Circuit had analyzed the case. In looking at the Teleflex patent, Justice Kennedy said, the appeals court made the mistake of considering what "a pedal designer writing on a blank slate" would have done to solve the problem of the pedal and the sensor. But the slate was not blank, he continued, and the Teleflex patent was essentially an upgrade of existing technology.
Justice Kennedy said the problem was not necessarily the Federal Circuit's overall approach, but rather its rigid way of applying a commonly used legal test. The test requires a person challenging a patent as obvious to identify a reason that would have prompted someone to combine two or more previous inventions, such as published articles suggesting such a combination. This has made it difficult to attack a patent as obvious, and has often precluded summary judgment, instead requiring an expensive jury trial.
Justice Kennedy said that this test, in the Federal Circuit's hands, had led to a "constricted analysis" that paid too much attention to an inventor's motivation and too little to a simpler inquiry: whether "there existed at the time of invention a known problem for which there was an obvious solution." The Teleflex patent fit that description, he said.
The federal government, which had sided with KSR, argued that the Federal Circuit's approach had led to the granting of too many patents to obvious inventions. Pharmaceutical and biotechnology industry groups, entering the case for Teleflex, argued that innovation would suffer if patents became too hard to defend.
In a sense, the case presented a moving target. While the KSR appeal was pending, the Federal Circuit issued several decisions reflecting openness to challenges to patents as unworthy because of obviousness. "Those decisions, of course, are not before us now," Justice Kennedy said.
Court Sides With Microsoft
WASHINGTON, April 30 (AP) ?- The Supreme Court sided with the Microsoft Corporation on Monday, finding that patent law does not apply to software sent to foreign countries.
In a 7-1 decision, the court rejected AT&T's position that it was entitled to damages for every Windows-based computer made outside the United States using technology that compresses speech into computer code.
AT&T had said computers running the Windows operating system infringed on its technology for a digital speech coder system.
The decision could affect other lawsuits against Microsoft and save it billions because of the global scope of its operations.
The Supreme Court said software should be treated like exported blueprints and schematics.
--------------------------------------------
Barnaby Feder contributed reporting.
Re: High Court Puts Limits on Patents - long over due reform
BumbleBeeBoogie wrote:Pharmaceutical and biotechnology industry groups, entering the case for Teleflex, argued that innovation would suffer if patents became too hard to defend.
Not surprising that pharmaceutical companies argued in favor of the more restrictive approach that the supreme court rejected. The drug companies have been "reinventing" their most profitable products --
re-patenting a drug based on some minor change in the formula -- for some time now. It will be interesting to see what effect, if any, this decision will have on that practice.
Re: High Court Puts Limits on Patents - long over due reform
joefromchicago wrote:BumbleBeeBoogie wrote:Pharmaceutical and biotechnology industry groups, entering the case for Teleflex, argued that innovation would suffer if patents became too hard to defend.
Not surprising that pharmaceutical companies argued in favor of the more restrictive approach that the supreme court rejected. The drug companies have been "reinventing" their most profitable products --
re-patenting a drug based on some minor change in the formula -- for some time now. It will be interesting to see what effect, if any, this decision will have on that practice.
Joe, you are correct. The drug companies have been playing this game for years to extend their patents, keep their profits high, and keep the price of drugs high.
BBB
@BumbleBeeBoogie,
Found a thread that goes back several years. Id like to recall , as one of the BIG things that happened this year was the USSC decision to NOT allow the patenting of gene discoveries. This is based upon an older USSC decision that states that "ANY THING THAT IS DISCOVERED IN NATURE IS NOT PATENTABLE"
We discovered a natural oil chomping bacterium in the late 1980's and my boss, at the time, wanted to seek patent protection of which we were denied based on the "mere discovery of a naturally occurring microbe'. SO the same thing now applies to the genome. HOWEVER, should it be that science creates a new gene, that IS patentable
PUBLIC LOG
Quote:
The U.S. Supreme Court finally ruled today on patenting breast-cancer genes. The ruling found that naturally occurring genes aren't patentable. If you make a synthetic version, however, that is your own work.
"The Court's decision strikes a middle ground that likely will not be particularly disruptive," Tom Goldstein, a Harvard Law School professor and publisher of SCOTUSblog, wrote in his publication's liveblog about the ruling.
Scientists from Myriad Genetics in Utah were the first to find and isolate BRCA1 and BRCA2, two major genes that affect people's chances of getting hereditary breast, ovarian and other cancers. The company holds numerous patents relating to those discoveries, which opponents say is unreasonable, because genes are products of nature, not patentable inventions. The case made its way to the Supreme Court because one group—including doctors, researchers and patient advocacy organizations—has been challenging Myriad Genetics' BRCA1 and BRCA2 patents since 2009.
Among Myriad's patents are ones that say the company has the rights to any isolated BRCA1 and BRCA2 genes. That means it has the exclusive right to offer testing for those genes, since you gotta isolate 'em to test for 'em. Yes, those are the same tests that, for example, Angelina Jolie took before deciding to get a preventative double mastectomy.
The new ruling says that even when isolated, naturally occurring genes aren't patentable because they're a product of nature, just like Myriad Genetics' opponents originally claimed. It doesn't matter that Myriad Genetics invested a lot of money, time and talent into finding BRCA1 and BRCA2. "Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry," Justice Clarence Thomas wrote in the court's opinion. §101 distinguishes between patentable inventions and un-patentable abstractions.